相关实验视频
Updated: Aug 7, 2026

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
Published on: January 12, 2017
标准或扩展淋巴切除术用于肌肉侵入性膀癌
Seth P Lerner1, Catherine Tangen1, Robert S Svatek1
1From Baylor College of Medicine (S.P.L.) and the University of Texas M.D. Anderson Cancer Center (A.M.K.), Houston, the University of Texas Health San Antonio (R.S.S.) and CHRISTUS Santa Rosa Medical Center Hospital (I.M.T.), San Antonio, and the University of Texas Southwestern Medical Center, Dallas (A.I.S.) - all in Texas; Stanford University, Stanford (E.S.), Norris Comprehensive Cancer Center, University of Southern California, Los Angeles (S.D., A.S.), and City of Hope Medical Center, Duarte (S.K.P.) - all in California; SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center - both in Seattle (C.T., M.P.); the Ohio State University, Columbus (K.S.P.); the University of Chicago, Chicago (N.D.S.); McGill University Health Center, Montreal (W.K.); the Bladder Cancer Advocacy Network, SWOG Advocates, Pittsford, NY (R.B.); Oregon Health and Science University, Portland (T.M.K.); the University of Michigan, Ann Arbor (A.A.); the University of Colorado, Aurora (F.G.L.R.); Brigham and Women's Hospital, Boston (A.S.K.); Fox Chase Cancer Center, Philadelphia (D.J.C.); and Oschsner Medical Center, Jefferson, LA (D.J.C.).
扩展淋巴切除术并没有改善肌肉侵入性膀癌患者的存活率,这些患者接受了激进的囊切除术. 与标准淋巴切除术相比,这种方法也增加了术后并发症和死亡率.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 手术瘤学手术瘤学
- 在瘤学瘤学.
背景情况:
- 扩展淋巴切除术与标准淋巴切除术在接受激进囊切除术的肌肉侵入性膀癌患者中的疗效尚不清楚.
- 确定最佳的淋巴切除术程度对于改善膀癌治疗患者的结果至关重要.
研究的目的:
- 在局部肌肉侵入性膀癌患者中,比较扩展淋巴切除术和标准淋巴切除术之间的无病生存率和整体生存率.
- 评估与扩展淋巴切除术相关的安全性和术后发病率.
主要方法:
- 一项随机对照试验涉及592名患有局部肌肉侵入性膀癌 (临床阶段T2-T4a,N0-N2) 的患者,他们被分配到标准或扩展性淋巴切除术中.
- 随机化被新辅助化疗,瘤阶段和性能状态分层.
- 主要结局是无病生存期;整体生存期和安全性也被评估.
主要成果:
- 与标准淋巴切除术相比,扩展淋巴切除术没有显著改善5年无病生存率 (56%vs. 60%) 或整体存活率 (59%vs. 63%).
- 扩展淋巴切除术组的3-5级不良事件率 (54%对44%) 和90天死亡率 (7%对2%) 较高.
结论:
- 扩展淋巴切除术与肌肉侵入性膀癌患者进行激进囊切除术的改善生存结果无关.
- 扩展淋巴切除术与术后发病率和死亡率的增加有关,这表明标准淋巴切除术可能更可取.

